In a letter issued on Tuesday to Glenmark's US subsidiary Glenmark Generics Inc USA, the USFDA said the marketing of codeine sulphate 30 mg and 60 mg tablets by the firm in the US violated the Federal Food, Drug, and Cosmetic Act. When contacted, a Glenmark Pharmaceuticals spokesperson said, in compliance with the conditions of the warning letter, Glenmark will cease distribution of their codeine sulphate tablets within the timelines indicated by the FDA. "It must also be noted that this warning letter does not constitute a product recall," he said, adding sales of codeine sulphate tablets were minimal and the impact on Glenmark's financial performance was insignificant. In its letter, the USFDA said: "Based upon our information, there are no FDA-approved applications on file for the above drug products. The marketing of these products without an approved new drug application constitutes a violation (of the Act)." While asking the company to respond to its letter within 15 days, the health regulator has given Glenmark 90 days time to stop manufacturing new products and 180 days to stop further shipment of the existing products. (PTI) bl For full details for GMKPF click here.
![]()
Email Print Archives Feedback Email Article Link
Close X
Related News [GMKPF]
UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
Thursday December 3 12:30 PM
* Attendance is strictly limited and are filled on a first-come, first-served basis.
The TradingMarkets Directory
Stocks
Options
Forex
E-mini/Futures
How to Trade
Tools
PowerRatings
Blogs
|